{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:40:50Z","timestamp":1787701250214,"version":"build-2784847793"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30\u2005mg\/kg) and zinlirvimab (10 or 30\u2005mg\/kg), in virologically suppressed people with HIV-1 susceptible (IC90 \u2264 2\u2005\u03bcg\/mL) to both (primary cohort, n = 20) or either (pilot cohort, n = 10) bNAb. We describe resistance analyses through Week (W) 26.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. Low copy number genotyping methods for capsid and a 1\u2005kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Virologic failure was observed in 1\/30 participants. This primary cohort participant had HIV RNA 155\u2005copies\/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, experienced virologic rebound at W26 (55 and 72\u2005copies\/mL) and restarted oral antiretrovirals. In exploratory analyses, neither had emergent lenacapavir resistance or altered bNAb susceptibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf559","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:01Z","timestamp":1762646401000},"page":"e212-e220","source":"Crossref","is-referenced-by-count":2,"title":["Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab"],"prefix":"10.1093","volume":"233","author":[{"given":"Lisa","family":"Selzer","sequence":"first","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-0614","authenticated-orcid":false,"given":"Sally","family":"Demirdjian","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8599-8173","authenticated-orcid":false,"given":"Brie","family":"Falkard","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5563-4505","authenticated-orcid":false,"given":"Jiani","family":"Li","sequence":"additional","affiliation":[{"name":"Bioinformatics, Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-4748","authenticated-orcid":false,"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Bioinformatics, Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E","family":"Collins","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Eron","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A","family":"VanderVeen","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[{"name":"Clinical Virology, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2026031304530545700_jiaf559-B1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/09540121.2015.1074653","article-title":"Lifelong antiretroviral therapy or HIV cure: the benefits for the individual patient","volume":"28","author":"Buell","year":"2016","journal-title":"AIDS Care"},{"key":"2026031304530545700_jiaf559-B2","doi-asserted-by":"crossref","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PLoS Med"},{"key":"2026031304530545700_jiaf559-B3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/13548506.2014.945601","article-title":"A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy","volume":"20","author":"Claborn","year":"2015","journal-title":"Psychol Health Med"},{"key":"2026031304530545700_jiaf559-B4","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1093\/cid\/ciac716","article-title":"Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries","volume":"75","author":"Cooper","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031304530545700_jiaf559-B5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031304530545700_jiaf559-B6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"2026031304530545700_jiaf559-B7","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"2026031304530545700_jiaf559-B8"},{"key":"2026031304530545700_jiaf559-B9"},{"key":"2026031304530545700_jiaf559-B10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"key":"2026031304530545700_jiaf559-B11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"2026031304530545700_jiaf559-B12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"2026031304530545700_jiaf559-B13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10\u20131074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"2026031304530545700_jiaf559-B14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 Antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"2026031304530545700_jiaf559-B15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat Med"},{"key":"2026031304530545700_jiaf559-B16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/QAI.0000000000003528","article-title":"Susceptibility screening of HIV-1 viruses to broadly neutralizing antibodies, teropavimab and zinlirvimab, in people with HIV-1 suppressed by antiretroviral therapy","volume":"98","author":"Selzer","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031304530545700_jiaf559-B17","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","article-title":"Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study","volume":"11","author":"Eron","year":"2024","journal-title":"Lancet HIV"},{"key":"2026031304530545700_jiaf559-B18","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/infdis\/jiaf159","article-title":"Lenacapavir plus 2 broadly neutralizing antibodies, teropavimab and zinlirvimab, for people with HIV-1 highly susceptible to either teropavimab or zinlirvimab","volume":"231","author":"Eron","year":"2025","journal-title":"J Infect Dis"},{"key":"2026031304530545700_jiaf559-B19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000002722","article-title":"Evaluation of broadly neutralizing antibody sensitivity by genotyping and phenotyping for qualifying participants to HIV clinical trials","volume":"88","author":"Moldt","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031304530545700_jiaf559-B20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/QAD.0000000000003792","article-title":"HIV-1 Envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection","volume":"38","author":"VanderVeen","year":"2024","journal-title":"AIDS"},{"issue":"D1","key":"2026031304530545700_jiaf559-B21","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1093\/nar\/gkaa1023","article-title":"GenBank","volume":"49","author":"Sayers","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2026031304530545700_jiaf559-B22","author":"Reeves"},{"key":"2026031304530545700_jiaf559-B23","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"Richman","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026031304530545700_jiaf559-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/13596535231220754","article-title":"Cross-resistance to entry inhibitors and lenacapavir resistance through week 52 in study CAPELLA","volume":"28","author":"Margot","year":"2023","journal-title":"Antivir Ther"},{"key":"2026031304530545700_jiaf559-B25","first-page":"457","article-title":"2025 update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top Antivir Med"},{"issue":"5","key":"2026031304530545700_jiaf559-B26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/jiaf050","article-title":"Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years","volume":"231","author":"Margot","year":"2025","journal-title":"J Infect Dis"},{"issue":"W1","key":"2026031304530545700_jiaf559-B27","doi-asserted-by":"crossref","first-page":"W213","DOI":"10.1093\/nar\/gkv404","article-title":"CATNAP: a tool to compile, analyze and tally neutralizing antibody panels","volume":"43","author":"Yoon","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026031304530545700_jiaf559-B28"},{"key":"2026031304530545700_jiaf559-B29","doi-asserted-by":"crossref","first-page":"e0127421","DOI":"10.1128\/mbio.01274-21","article-title":"Near-pan-neutralizing, plasma deconvoluted antibody N49P6 mimics host receptor CD4 in its quaternary interactions with the HIV-1 envelope trimer","volume":"12","author":"Tolbert","year":"2021","journal-title":"mBio"},{"key":"2026031304530545700_jiaf559-B30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 Escape by a highly broad and potent neutralizing antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"2026031304530545700_jiaf559-B31","doi-asserted-by":"crossref","first-page":"e1003342","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans","volume":"9","author":"Julien","year":"2013","journal-title":"PLoS Pathog"},{"key":"2026031304530545700_jiaf559-B32","doi-asserted-by":"crossref","first-page":"10510","DOI":"10.1128\/JVI.00552-10","article-title":"Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16","volume":"84","author":"Doores","year":"2010","journal-title":"J Virol"},{"key":"2026031304530545700_jiaf559-B33","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026031304530545700_jiaf559-B34","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/jac\/dkab503","article-title":"Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study","volume":"77","author":"Margot","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026031304530545700_jiaf559-B35","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","article-title":"Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir","volume":"226","author":"Margot","year":"2022","journal-title":"J Infect Dis"},{"key":"2026031304530545700_jiaf559-B36","doi-asserted-by":"crossref","first-page":"e70340","DOI":"10.1002\/jmv.70340","article-title":"Phenotypic characterization of replication-impaired lenacapavir-resistant HIV clinical isolates","volume":"97","author":"Demirdjian","year":"2025","journal-title":"J Med Virol"},{"key":"2026031304530545700_jiaf559-B37","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jac\/dkaa060","article-title":"Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients","volume":"75","author":"Marcelin","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026031304530545700_jiaf559-B38","doi-asserted-by":"crossref","first-page":"e00187\u201325","DOI":"10.1128\/mbio.00187-25","article-title":"Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir","volume":"16","author":"Hansen","year":"2025","journal-title":"mBio"},{"key":"2026031304530545700_jiaf559-B39","doi-asserted-by":"publisher","author":"Hagins","DOI":"10.1097\/QAD.0000000000004372"},{"key":"2026031304530545700_jiaf559-B40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"2026031304530545700_jiaf559-B41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"2026031304530545700_jiaf559-B42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 Neutralizing antibody signatures and application to epitope-targeted vaccine design","volume":"25","author":"Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"2026031304530545700_jiaf559-B43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1570162X20666211227161237","article-title":"The importance of tissue sanctuaries and cellular reservoirs of HIV-1","volume":"20","author":"Kalada","year":"2022","journal-title":"Curr HIV Res"},{"key":"2026031304530545700_jiaf559-B44","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3389\/fmicb.2019.02383","article-title":"Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms","volume":"10","author":"Jacobs","year":"2019","journal-title":"Front Microbiol"},{"key":"2026031304530545700_jiaf559-B45","doi-asserted-by":"publisher","author":"Taiwo","DOI":"10.1093\/cid\/ciaf375"},{"key":"2026031304530545700_jiaf559-B46","doi-asserted-by":"crossref","first-page":"e2845","DOI":"10.1093\/cid\/ciaa1754","article-title":"A high percentage of people with human immunodeficiency virus (HIV) on antiretroviral therapy experience detectable low-level plasma HIV-1 RNA following coronavirus disease 2019 (COVID-19)","volume":"73","author":"Peluso","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf559\/65215416\/jiaf559.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/1\/e212\/65215416\/jiaf559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/1\/e212\/65215416\/jiaf559.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:54:59Z","timestamp":1773392099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/1\/e212\/8314390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,5]]},"published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf559","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,11,5]]}}}